United Therapeutics CORP Form 4 insider transactions

United Therapeutics Corp's President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.

United Therapeutics Director Christopher Causey filed a Form 4 to correct previously overstated beneficial ownership following an unauthorized share transfer.

United Therapeutics CEO Martine Rothblatt executed stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed planned stock option exercises and subsequent sales of common stock under a Rule 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for a significant profit, pursuant to a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised and sold common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt exercised and sold common stock options totaling 8,000 shares over two days as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, exercised and sold common stock options totaling 8,000 shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 22,500 shares for approximately $9.9 million.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed pre-arranged sales of common stock totaling 8,000 shares from option exercises on October 7 and 8, 2025, under a 10b5-1 trading plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares on October 6, 2025, following option exercises.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed and sold common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock on October 1 and 2, 2025, under a 10b5-1 trading plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold 22,500 common shares on September 29, 2025, under a Rule 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock totaling 11,990 shares in late September 2025 under a Rule 10b5-1 trading plan.

United Therapeutics Corp's Chairperson and CEO, Martine A. Rothblatt, executed pre-arranged stock option exercises and subsequent sales of common stock on September 25 and 26, 2025.

United Therapeutics Director Christopher Causey exercised options and sold 1,000 shares.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late September 2025 under a 10b5-1 trading plan.

United Therapeutics Corporation's President and COO, Michael Benkowitz, executed a pre-planned sale of 22,500 shares of common stock for over $9.3 million after exercising stock options.

United Therapeutics CEO Martine Rothblatt executed pre-arranged stock option exercises and sales totaling 8,000 shares of common stock.

United Therapeutics Director Judy D. Olian sold 1,800 shares of common stock for approximately $747,767 through a pre-arranged trading plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics CEO Martine Rothblatt executed pre-planned stock option exercises and subsequent sales of common stock on September 17 and 18, 2025, under a 10b5-1 trading plan.

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, exercised and sold 4,000 common stock options on September 16, 2025, under a pre-arranged 10b5-1 trading plan.

United Therapeutics President and COO Michael Benkowitz executed pre-planned sales of common stock following option exercises on September 15, 2025.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, sold shares under a pre-arranged 10b5-1 trading plan.